Nkarta Inc (NKTX)

[jondoeuk]

Additional NKX101 and NKX019 clinical data expected by year-end. The data is expected to include safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses. Also, in June, the company filed a protocol amendment with the FDA for 019 to optimise the trial's design as they prepare for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide with lymphodepletion, in line with 101, and various expansion cohorts evaluating it in combination with rituximab.

[jondoeuk]

Cowen 3rd Annual Oncology Innovation Summit webcast https://wsw.com/webcast/cowen115/nktx/2047935

[crudeoil24]

Time for some momo/fomo to kick in. Let's go NKTX!

[crudeoil24]

Offering is now closed Company raised over $200M within a few sessions. Let's see if tutes accumulate NKTX shares today. Possibly 20.00+ today!

[stock1ace1]

20$

[crudeoil24]

NKTX is a great $$$$$ opportunity.

[crudeoil24]

Not a p&d. Some folks need to learn how to read a corporate balance sheet / and SEC filings.

[crudeoil24]

18.93 > > Looks like NKTX shelf placement is completed. Looks like another $200M in the kitty.

[Saving Grace]

Front Loaded Pump and Dump, They are trying to promote this to death before the Med Beds that cure anything and everything come out.

Japan is already using the Med Beds with indisputable results

Caveat Emptor! with this horseshit scam.

[JamBop]

That would be if the number 15 was the actual value. But why offer an actual value to someone as a valuable transaction?
Makes more sense that 15 is a discount.

[Gator44]

Shouldn't this open at $15 when the market opens for trading ?

[rynlrt]

Price target is 109. Wouldnt consider 18 high

[TheFinalCD]

thats assuming a high price of 18

Message in reply to:
That's only about 10M shares if @ 18.00 price NKTX could absorb that in one session. Could close shelf placement this week + have plenty of cash for their operations & expenses.

[crudeoil24]

That's only about 10M shares if @ 18.00 price NKTX could absorb that in one session. Could close shelf placement this week + have plenty of cash for their operations & expenses.

[crudeoil24]

Turn your monitor upside down! lol

[TheFinalCD]

UP ON OFFERING NEWS

HAVE SEEN IT ALL NOW!!!

[crudeoil24]

I see > NKTX @ 19.84 now. Probably most traders are clueless. Maybe the upcoming big volume days will absorb the $150M shelf placement by April 30.

[TheFinalCD]

$NKTX Nkarta Announces Proposed Public Offering of Common Stock

$150M

[crudeoil24]

Thank you ! I wish Elon Musk buy 50 million shares! lol

NKTX

[TheFinalCD]

18.94 CONGRAT$

[crudeoil24]

PT > 109.00 > Mizuho Maintain Buys On Nkarta, Raises Price Target To $109

[crudeoil24]

NKTX > PHI SLAMMA JAMA!

[crudeoil24]

NKTX > 17.94

[jondoeuk]

Another group plans to test an anti-CD70 CAR-NK (with IL-15) in GBM. Knockout of NR3C1 (steroid receptor pathway) allows for the concurrent use of steroids without negating activity of the therapy

[jondoeuk]

More (preclinical data) from the same group

[jondoeuk]

A PhI is planned

[jondoeuk]

MICA and MICB, as well as ULBP 1-6 expression is tightly restricted in healthy cells, only upregulated during stress and cellular transformation [1], and are recognised by the NKG2D receptor, which activates NK cells [2]. However, looking at just AML, expression can vary [3,4].

So going forward, I hope to see a number of different combinations tested. Bortezomib can increase the cell surface expression of NKG2D ligands, resulting in the increased killing by NK cells [5]. Histone deacetylase inhibitors have also been shown to increase expression of NKG2D ligands [6-8]. Treatment resulted in increased recognition and increased sensitivity to NK cell lysis [9]. In addition, all-trans retinoic acid or valproic acid in patients with AML induced NKG2D ligands on the surface of leukemic cells [10,11].

Finally, the use of a PARP1 inhibitor, could increase AML leukemic stem cell killing [12].

Refs:
1 https://www.annualreviews.org/doi/full/10.1146/annurev-immunol-032712-095951
2 https://www.science.org/doi/10.1126/science.285.5428.727
3 https://www.jimmunol.org/content/189/3/1360.long
4 https://ashpublications.org/blood/article/105/9/3615/21291/Ligands-for-natural-killer-cell-activating
5 https://aacrjournals.org/cancerres/article/68/5/1546/542412/Selective-Induction-of-Expression-of-a-Ligand-for
6 https://aacrjournals.org/cancerres/article/65/23/11136/518911/Cancer-Cells-Become-Susceptible-to-Natural-Killer
7 https://aacrjournals.org/cancerres/article/65/14/6321/518359/Natural-Killer-Cell-Mediated-Lysis-of-Hepatoma
8 https://www.pnas.org/doi/abs/10.1073/pnas.1008522107
9 https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/2045-3329-2-8
10 https://www.sciencedirect.com/science/article/pii/S0006497120482278
11 https://www.frontiersin.org/articles/10.3389/fimmu.2020.580328/full
12 https://cancerdiscovery.aacrjournals.org/content/9/9/OF13

[crudeoil24]

Let's go NKTX .....

[jondoeuk]

PR https://www.globenewswire.com/news-release/2022/04/25/2427988/0/en/Nkarta-Announces-Positive-Preliminary-Dose-Finding-Data-for-Two-Lead-Engineered-Natural-Killer-Cell-Programs.html

Slides https://ir.nkartatx.com/static-files/6d097f5f-2f67-4e80-8903-2c96b455b244

[crudeoil24]

PT > 81.00 > Cowen.

[Just-Keep-Trying]

And you too, Sir, did you grab any of this today?????????? Or, are you just talking about it??????

[Just-Keep-Trying]

Did you grab any of this today?????????? Or, are you just talking about it??????

[crudeoil24]

Ongoing shelf placement will drain any gains >

NKTX

[crudeoil24]

Trading float is 19M

NKTX

[crudeoil24]

Shares of Nkarta Inc. (NKTX) skyrocketed 92.8% in very active morning trading, enough to make the stock the biggest gainer and most active listed on major U.S. exchanges, after the biopharmaceutical company announced positive results from a Phase 1 trial of its cancer treatments. The rally comes after the stock closed at a record low of $7.77 on Friday. The company said its NKX101 and NKX019 co-lead candidates showed "striking single-agent activity" in a heavily pretreated patient populations, with an "exceptional safety provide" without side effects associated with CAR T cell therapies. Cowen analyst Salim Syed reiterated his buy rating and $81 stock price target, which implies TK% upside from current levels. "Investor sentiment was pretty low going into this readout," Syed wrote in a note to clients. "And of course, we still need durability data and more n, but showing these responses today, is a major plus, and street trading valuations should now move substantially higher for both programs." The stock has now lost 2.4% year to date, while the iShares Biotechnology ETF (IBB) has dropped 19.7% and the S&P 500 has declined 11.1%.

-Tomi Kilgore


(END) Dow Jones Newswires

[crudeoil24]

NKTX @ 15.15 up 96 % after positive CC.

[TheFinalCD]

previous close 7.77 almost +$10 WOW

[crudeoil24]

Data @ CC > 8:00AM EST

NKX101 – 3 of 5 patients with relapsed / refractory AML treated with a three-dose regimen consisting of 1B or 1.5B CAR NK cells per dose achieved complete response with full hematologic recovery (60% CR rate); 2 of 3 CRs are MRD negative

NKX019 – 5 of 6 patients with relapsed / refractory NHL treated with a three-dose regimen consisting of 1B CAR NK cells per dose achieved response (83% ORR) and 3 of 6 achieved complete response (50% CR rate); responses included DLBCL

No cytokine release syndrome (CRS), neurotoxicity or graft versus host disease (GvHD) reported for either program

Higher dose regimen of 1.5 billion x 3 doses of CAR NK cells is being evaluated in both programs

Updated data will be submitted for presentation at a future medical meeting

Conference call scheduled for today, April 25 at 8:00 am ET

[jondoeuk]

Link to webcast https://www.veracast.com/webcasts/clients/webcasts/KdH3SE.cfm

[jondoeuk]

The company will host a conference call on Mon, April 25, at 8:00 am ET to review clinical data from its ongoing PhI clinical trials assessing two lead clinical programs, NKX101 and NKX019. Leading investigators from the two clinical trials will join management in the discussion.

[jondoeuk]

AACR PR https://www.globenewswire.com/news-release/2022/04/08/2419482/0/en/Nkarta-Presents-New-Preclinical-Data-from-Engineered-NK-Cell-Platform-at-AACR-Annual-Meeting-2022.html

Posters https://www.nkartatx.com/file.cfm/75/docs/2022_aacr_5187_hansen_multiomics_car-nk_translational.pdf

https://www.nkartatx.com/file.cfm/75/docs/2022_aacr_5511_vejiga_hypoimmune_masking.pdf

https://www.nkartatx.com/file.cfm/75/docs/2022_aacr_5512_guo_cd70.pdf

https://www.nkartatx.com/file.cfm/75/docs/2022_aacr_6004_morisot_mm_preclinical_model.pdf

[jondoeuk]

NKX101 (R/R AML and higher-risk MDS): Dose escalation should be finished in Q3, dose expansion in H1 2023, and potential pivotal trial(s) in 2H 2023.

NKX101 (certain solid tumours): They will amend the IND in Q4 and plan to start a PhI sometime in 2023.

NKX019 (CD19+ B-cell malignancies): Dose escalation should be finished in Q3, dose expansion in H1 2023, and potential pivotal trial(s) in 2H 2023.

As for the programs with CRSP, no info to when they could be moving into the clinic as of yet.

[jondoeuk]

AACR abstracts

CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-ß for cancer immunotherapy https://www.abstractsonline.com/pp8/#!/10517/presentation/17731

Development of multiomics approaches to evaluate NKG2D ligand dynamics and anti-tumor immune responses during CAR-NK treatment https://www.abstractsonline.com/pp8/#!/10517/presentation/17508

Immune masking strategies to extend the pharmacokinetics of allogeneic cell therapies https://www.abstractsonline.com/pp8/#!/10517/presentation/17730

Surveying surface antigen expression in multiple myeloma preclinical models https://www.abstractsonline.com/pp8/#!/10517/presentation/17960

[jondoeuk]

Another company working on a healthy donor anti-CD70 CAR-NK

[jondoeuk]

The CMO was at this

[jondoeuk]

The FDA has granted ODD to NKX101 for treatment of AML.

[jondoeuk]

ASH PR https://www.globenewswire.com/news-release/2021/12/13/2351140/0/en/Nkarta-Presents-NKX019-Trial-in-Progress-Poster-at-the-2021-ASH-Annual-Meeting-and-Exposition.html

Poster https://www.nkartatx.com/file.cfm/75/docs/NKX019_TiP_poster-ASH_2021-3868_Dickinson_et_al_web.pdf

[jondoeuk]

From the PR

Title: A Combined Strategy of CD70 CAR Co-expression with Membrane-bound IL-15 and CISH Knockout Results in Enhanced NK Cytotoxicity and Persistence

This study illustrates multiple approaches to modify NK cells to target CD70, an antigen highly expressed in haematological malignancies and solid tumours, including renal cell carcinoma. Optimal CD70 chimeric antigen receptor (CAR) candidates were identified using high throughput screening approaches. Preclinical results showed that a combined editing and engineering strategy to armour primary NK cells via co-expression of the CD70 CAR and a membrane bound form of IL-15 (mbIL-15), together with knockout of CISH and CD70 genes using the CRISPR/Cas9 system enhanced the persistence in culture and the cytotoxicity of the cells against multiple tumour cell lines. The knockout of CISH also supported the resistance of primary NK cells to suppressive elements active in the tumour microenvironment.

Title: CISH Gene-knockout Anti-CD70-CAR NK Cells Demonstrate Potent Anti-tumor Activity Against Solid Tumor Cell Lines and Provide Partial Resistance to Tumor Microenvironment Inhibition

Primary NK cells engineered with CD70 chimeric antigen receptor (CAR), membrane bound form of IL-15 (mbIL-15) and knockout of CISH and CD70 genes using the CRISPR/Cas9 system could be produced efficiently, demonstrating consistent knockout and transduction efficiency across donors. Memory like NK cell differentiation of the gene edited NK cells was achieved using a modified K562 stimulatory cell line expressing membrane-bound IL-15 and 4-1BBL with the addition of IL-12 and IL-18 during expansion. Various gene editing candidates were assessed; the knockout of CISH in particular enhanced not only tumour cell killing by CD70 CAR NK cells, but also their persistence in culture and resistance to suppressive molecules associated with the tumour microenvironment, such as TGFß and adenosine.

Title: Potentiating the Large-Scale Expansion and Engineering of Peripheral Blood-Derived CAR NK Cells for Off-the-Shelf Application

The study highlights novel methods for scaling the expansion of engineered NK cells to potentially supply a life cycle's worth of commercial off-the-shelf product from a single donor. The methods entail sequential pulses with a proprietary K562 stimulatory cell line in the presence of IL-2 and use of IL-12 and IL-18 to achieve differentiation into memory-like NK cells. When these methods were used to achieve cell expansion greater than even 2 billion-fold, CAR expression was increased on the NK cell surface, engineered cells with CISH gene knockout, CAR and mbIL-15 were preferentially enriched during expansion, and the chromosomal integrity of the cells was well maintained.

Title: KIR Haplotype Can Inform Donor Selection in the Production of Allogeneic Memory-Like CAR NK Cells for Clinical Application

Study findings suggest that the profile of activating and inhibitory KIR genes expressed by healthy donors' NK cells may serve as a future criterion for selecting donors whose NK cells can be engineered for enhanced cytotoxic activity. The optimal KIR profile may depend on the process used to generate NK cells. Engineered CD19 CAR NK cells whose expansion includes IL-12 and IL-18 added to a proprietary K562 stimulatory cell line containing mbIL-15 and 15-41BBL stimulatory cells showed enhanced potency and upregulation of NK memory associated cell surface markers and natural cytotoxicity markers. Finally, donor KIR haplotype correlated best with CAR NK activity in cells expanded in the presence of IL-12 and IL-18, showing that donor selection and expansion methods must be considered together for development of optimal CAR NK therapies.

[jondoeuk]

SITC posters https://www.nkartatx.com/file.cfm/75/docs/Nkarta_SITC-2021-A-Combined-Strategy-of-CD70-CAR-Co-expression-with-Membrane-bound-IL-15_16439_Trager.pdf

https://www.nkartatx.com/file.cfm/75/docs/Nkarta_SITC-2021-CISH-Gene-Knockout-Anti-CD70-CAR-NK-poster_113_Trager.pdf

https://www.nkartatx.com/file.cfm/75/docs/Nkarta_SITC-2021-Potentiating-the-Large-Scale-Expansion-and-Engineering-of-Peripheral-Blood-CAR-NK-Cells-poster_151_Whang.pdf

https://www.nkartatx.com/file.cfm/75/docs/Nkarta_SITC-2021-KIR-Haplotype-Can-Inform-Donor-Selection-poster_128_Lemar.pdf

[jondoeuk]

Upcoming investor conferences:

Cowen 5TH Annual IO Next Summit
Nov 15
11:15 a.m. ET - fireside chat presentation
https://wsw.com/webcast/cowen105/nktx/2046618

Stifel Virtual Healthcare Conference
Nov 17
2:00 p.m. ET – fireside chat presentation
https://wsw.com/webcast/stifel58/nktx/2133540

Evercore ISI 4TH Annual HealthCONx Conference
Dec 1
4:20 p.m. ET – fireside chat presentation
https://wsw.com/webcast/evercore21/nktx/2399574